AADAC抗体

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human fetal liver tissue, Human liver cancer tissue, Primary antibody: P07723(AADAC Antibody) at dilution 1/550, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human colon cancer tissue using P07723(AADAC Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P07723(AADAC Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The arylacetamide deacetylase (AADAC) antibody is a research tool targeting the AADAC enzyme, a hydrolytic protein primarily expressed in the liver and gastrointestinal tract. AADAC plays a critical role in xenobiotic metabolism, catalyzing the deacetylation of arylacetamide substrates, including certain drugs (e.g., rifamycin) and environmental toxins. It also participates in lipid metabolism, influencing triglyceride hydrolysis and cholesterol homeostasis. Dysregulation of AADAC has been linked to metabolic disorders, drug toxicity, and cancers, particularly hepatocellular carcinoma and colorectal cancer.

AADAC antibodies, typically developed in hosts like rabbits or mice, enable the detection and quantification of AADAC protein levels in tissues or cell lysates via techniques like Western blotting, immunohistochemistry, and ELISA. These antibodies aid in studying AADAC's tissue distribution, regulatory mechanisms, and pathological roles. Recent research highlights AADAC's potential as a biomarker for metabolic syndrome or chemotherapeutic response. However, challenges remain in standardizing antibody specificity due to sequence homology with other esterases. Ongoing studies focus on clarifying AADAC's interactions with endogenous substrates and its impact on drug efficacy, underscoring its therapeutic and diagnostic relevance.